Xencor, Inc. (XNCR) – What Are Analysts Saying About This Stock?

Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been given an average rating of “Moderate Buy” by the eleven analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $44.00.

XNCR has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price target on shares of Xencor from $21.00 to $37.00 and gave the stock a “neutral” rating in a research report on Thursday. Barclays set a $45.00 price objective on shares of Xencor and gave the company an “overweight” rating in a research report on Monday, October 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research report on Monday, September 21st. Wedbush upped their price objective on Xencor from $30.00 to $45.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 27th. Finally, Truist Financial increased their target price on Xencor from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, October 27th.

Read Our Latest Stock Analysis on Xencor

Xencor Stock Performance

Shares of NASDAQ:XNCR opened at $34.01 on Friday. The stock’s 50-day simple moving average is $28.09 and its two-hundred day simple moving average is $18.55. The stock has a market capitalization of $2.55 billion, a price-to-earnings ratio of -21.39 and a beta of 0.78. Xencor has a 52-week low of $10.38 and a 52-week high of $40.60.

Xencor (NASDAQ:XNCR – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.50 EPS for the quarter, beating the consensus estimate of ($0.33) by $0.83. The firm had revenue of $116.52 million during the quarter, compared to analyst estimates of $63.00 million. Xencor had a negative net margin of 58.79% and a negative return on equity of 21.28%. The business’s revenue for the quarter was up 453.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.08) EPS. As a group, equities analysts forecast that Xencor will post -2.61 earnings per share for the current fiscal year.

Insider Buying and Selling at Xencor

In other Xencor news, Director Richard Ranieri sold 81,252 shares of the company’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $39.25, for a total transaction of $3,189,141.00. Following the sale, the director directly owned 18,514 shares in the company, valued at $726,674.50. This represents a 81.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 5.08% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC bought a new stake in Xencor during the third quarter valued at about $25,000. Bessemer Group Inc. increased its stake in Xencor by 18.7% during the 3rd quarter. Bessemer Group Inc. now owns 1,791 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 282 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of Xencor in the second quarter worth $30,000. Allworth Financial LP acquired a new stake in shares of Xencor during the second quarter worth $55,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Xencor during the third quarter valued at $95,000.

Xencor Company Profile

(Get Free Report)

Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target. Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets.

Recommended Stories

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.